The S&P 500 Biotech index rose as much as 25% last year after falling as low as 8% during the apex of last year’s sell-offs. Now, downward pressure is helping leveraged inverse funds like the Direxion Daily S&P Biotech Bear 3X Shares (LABD). “Lossmaking pharmaceutical and biotech companies dominate the list of US stocks most […]
The post Biotech Rose with the Virus. Now It’s Falling Behind appeared first on ETF Trends.